










































Phosphorylation of Synaptic Vesicle Protein 2A at Thr84 by
Casein Kinase 1 Family Kinases Controls the Specific Retrieval
of Synaptotagmin-1
Citation for published version:
Zhang, N, Gordon, SL, Fritsch, MJ, Esoof, N, Campbell, DG, Gourlay, R, Velupillai, S, Macartney, T,
Peggie, M, van Aalten, DMF, Cousin, MA & Alessi, DR 2015, 'Phosphorylation of Synaptic Vesicle Protein
2A at Thr84 by Casein Kinase 1 Family Kinases Controls the Specific Retrieval of Synaptotagmin-1' Journal
of Neuroscience, vol. 35, no. 6, pp. 2492-2507. DOI: 10.1523/JNEUROSCI.4248-14.2015
Digital Object Identifier (DOI):
10.1523/JNEUROSCI.4248-14.2015
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright © 2015 Zhang et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/3.0),
which permits unrestricted use, distribution and reproduction in any
medium provided that the original work is properly attributed.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Cellular/Molecular
Phosphorylation of Synaptic Vesicle Protein 2A at Thr84 by
Casein Kinase 1 Family Kinases Controls the Specific
Retrieval of Synaptotagmin-1
Ning Zhang,1* XSarah L. Gordon,2* XMaximilian J. Fritsch,1* Noor Esoof,1* XDavid G. Campbell,1 Robert Gourlay,1
Srikannathasan Velupillai,1 XThomas Macartney,1 XMark Peggie,1DaanM.F. van Aalten,1Michael A. Cousin,2*
and Dario R. Alessi1*
1Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland,
United Kingdom, and 2Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, Scotland, United Kingdom
Synapticvesicleprotein2A(SV2A) isaubiquitouscomponentof synapticvesicles (SVs). Ithasroles inbothSVtraffickingandneurotransmitter
release.We demonstrate that Casein kinase 1 familymembers, including isoforms of Tau–tubulin protein kinases (TTBK1 andTTBK2), phos-
phorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84).
These residues are also phosphorylated in vivo, and the phosphorylation of Thr84withinCluster-2 is essential for triggering binding to theC2B
domain of human synaptotagmin-1.We show by crystallographic and other analyses that the phosphorylated Thr84 residue binds to a pocket
formedby three conserved Lys residues (Lys314, Lys326, andLys328) on the surface of the synaptotagmin-1 C2Bdomain. Finally, we observed
dysfunctionalsynaptotagmin-1retrievalduringSVendocytosisbyablating itsphospho-dependent interactionwithSV2A,knockdownofSV2A,
or rescuewithaphosphorylation-nullThr84SV2Amutant inprimaryculturesofmouseneurons.This studyreveals fundamentaldetailsofhow
phosphorylation of Thr84 on SV2A controls its interaction with synaptotagmin-1 and implicates SV2A as a phospho-dependent chaperone
required for the specific retrieval of synaptotagmin-1 during SV endocytosis.
Key words: CK1; SV2A; synaptotagmin
Introduction
Synaptic vesicle protein 2 (SV2A, SV2B, and SV2C) isoforms are
all integral 12 transmembrane domain synaptic vesicle (SV) pro-
teins. SV2A is the most widely distributed SV2 isoform and is
ubiquitously expressed in the CNS, whereas SV2B is brain spe-
cific with SV2C the minor isoform (Buckley and Kelly, 1985;
Bajjalieh et al., 1994).
SV2A knock-out mice are normal at birth but fail to grow and
experience severe seizures before premature death after 3 weeks
attributable to multiple neural and endocrine deficits (Crowder
et al., 1999), indicating that SV2A plays key roles in postnatal
brain function. It has been proposed to function as a positive
effector of SV exocytosis, potentially by binding calcium
(Mendoza-Torreblanca et al., 2013). All SV2 isoforms possess an
N-terminal cytoplasmic domain that interacts with another inte-
gral SV protein, synaptotagmin-1 (Syt1; Schivell et al., 1996;
Schivell et al., 2005; Lazzell et al., 2004). Synaptotagmin-1 is the
key Ca2 sensor for evoked synchronous neurotransmitter re-
lease at the synapse (Brose et al., 1992; Geppert et al., 1994), and
thus its efficient incorporation into newly formed SVs during
endocytosis is essential tomaintain the fidelity of neurotransmis-
sion. Disruption of SV2A retrieval during SV endocytosis results
in accumulation of synaptotagmin-1 on the plasmamembrane of
central nerve terminals (Yao et al. 2010), suggesting that SV2A
may be required for efficient packaging of this essential calcium-
sensing protein into SVs.
Relatively little is understood regardinghowSV2 isoforms are regu-
lated. Global phosphorylation site mass spectrometry studies have re-
vealed that SV2A is potentially phosphorylated on at least 10 residues
within its N-terminal cytoplasmic region (http://www.phosphosite.
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org/proteinAction.do?id8509&showAllSitestrue). To our
knowledge, only one other investigation has analyzed the regula-
tion of SV2A by phosphorylation (Pyle et al., 2000). This study
identified an SV-associated kinase that phosphorylated the
N-terminal cytoplasmic domain of SV2A. In gel kinase assays and
the use of a Casein kinase 1 (CK1) inhibitor (CK1-7) suggested
that this kinase was a member of the CK1 group of eukaryotic
protein kinases (Pyle et al., 2000). Intriguingly, in vitrophosphor-
ylation of a recombinant N-terminal fragment of SV2A compris-
ing the cytoplasmic domain by CK1 increased its ability to
interact with recombinant synaptotagmin-1 approximately
threefold (Pyle et al., 2000).
To date, no studies have determined the site(s) phosphory-
lated by CK1 isoforms within the SV2A N-terminal cytoplasmic
domain and how phosphorylation of these residues stimulates
recruitment of synaptotagmin-1 and/or influences SV traffick-
ing. In this study, we demonstrate that CK1 and Tau–tubulin
protein kinase (TTBK) isoforms efficiently phosphorylate the
N-terminal cytoplasmic domain of SV2A within two constella-
tions, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2
(Ser80, Ser81, and Thr84). We demonstrate that phosphory-
lation of Thr84 in Cluster-2 is key in triggering binding to
synaptotagmin-1. Crystallographic analysis revealed that the
phosphorylated Thr84 residue specifically bound to a pocket
formed by three conserved Lys residues (Lys314, Lys326, and
Lys328) on the surface of the synaptotagmin-1 C2B domain. Fi-
nally, we present evidence that phosphorylation of SV2A at
Cluster-2 is essential for the efficient retrieval of synaptotagmin-1
during SV endocytosis.
Materials andMethods
Materials. Synaptotagmin-1–pHluorin (Syt1–pHluorin) and synapto-
physin–pHluorin constructs were provided by Prof. V. Haucke (Leibniz
Institute of Molecular Pharmacology, Berlin, Germany) and Prof. L. La-
gnado (University of Sussex, Sussex, UK). Neurobasal media, B-27 sup-
plement, penicillin/streptomycin, minimal essential medium (MEM),
Lipofectamine 2000, and anti-rabbit Alexa Fluor 568were obtained from
Invitrogen. Recombinant human CK1 family kinases TTBK2[1–316]
(DU (Dundee University) number 38313), TTBK1[1–1321, full length]
(DU number 34496), Vaccinia-related kinase 1 (VRK1)[1–396, full
length] (DU number 34413), CK11[1–337, full length] (DU number
329), CK1[1–415, full length] (DU number 19064), CK1[1–416, full
length] (DU number 5127), CK11[1–422, full length] (DU number
31197), SV2A[1–160] (DUnumber 38732), SV2A[1–160] Cluster-1mu-
tant (DU number 39656), SV2A[1–160] Cluster-1 mutant (DU number
44015), and SV2A[1–160] Cluster-1  Cluster2 mutant (DU number
40838) were all expressed in Escherichia coli with the indicated
N-terminal glutathione S-transferase (GST) or maltose binding protein
(MBP) tag. The SV2A full-length proteins [wild type (WT) or eight Ser/
Thr to A mutants] with GST tag were expressed and purified from
HEK293 cells transfected with corresponding constructs [WT, DUnum-
ber 38880; eight S(T)/A, DU number 44610]. TheWT and phosphoryla-
tion site(s) mutants full-length SV2A proteins were expressed and
purified from HEK293 cells for analyzing the phosphorylation on SV2A
in vivo by mass spectrometry. All other reagents were obtained from
Sigma-Aldrich. All recombinant proteins, plasmids, and antibodies gen-
erated for the present study are available on request and are described in
additional detail on our reagents website (https://mrcppureagents.
dundee.ac.uk/).
General methods. Recombinant DNA procedures were performed
using standard protocols. Mutagenesis was performed using the
QuikChange site-directed mutagenesis kit (Stratagene) with KOD poly-
merase (Novagen). DNA constructs were purified from E. coli DH5
using a maxi prep kit (Qiagen) according to the instructions of the man-
ufacturer. Verification of the constructs was performed by the Sequenc-
ing Service [Medical Research Council Protein Phosphorylation Unit
(MRC–PPU), College of Life Sciences, University of Dundee, Dundee,
Scotland, UK; ]. DNA for bacterial protein expression was transformed
into E. coli BL21-CodonPlus (DE3)-RIL cells (Stratagene).
Plasmid generation. Mouse SV2A was amplified from IMAGE
EST6493509 using KOD Hot Start DNA Polymerase (Merck Millipore),
cloned into pSC-b (Agilent), and sequenced to completion. This was
then ligated into the BglII NotI sites in pCMV mCerulean (mCer) N1
(Anggono et al., 2006). Mutations and shRNA-resistant versions were
created using the Quick Change method (Agilent) but using KOD DNA
Hot Start polymerase. SV2A–pHluorin was created in a Clontech
EGFP–C1 backbone by replacing EGFP with human SV2A using XhoI
andAgeI restriction enzymes. The fluorescent pHluorin proteinwas then
inserted between amino acids 197 and 198 at a PclI restriction enzyme
site (DU number 42587).
SV2A knockdown was achieved using the published oligonucleotide
sequence (GAATTGGCTCAGCAGTATGttcaagagaCATACTGCTGAG
CCAATTC) against the rat sequence of SV2A that is identical to the
mouse sequence (shRNA1; Dong et al. 2006). Oligonucleotides were
ligated into the BglII HindIII sites of pSUPER mCer (Clayton et al.,
2010). The SYN1 promoter-driven pHluorin–rSYT1–BGH pA cassette
was amplified by adding flanking BglII and SmaI restriction sites and
ligated into either vectors pSuper.Neo mCer or pSuper.Neo mCer
mSV2A shRNA1 after digestion.
Antibodies. The following antibodies were raised in sheep by the Divi-
sion of Signal Transduction Therapy at the University of Dundee and
affinity purified against the indicated antigens: anti-SV2A (S290D, first
bleed; raised against residues 1–160 of human SV2A), anti-phospho-
SV2A T84 (S679D, third bleed; raised against residues 77–91 of human
SV2A: RRGGASSDApTEGHDEDDRR), and anti-phospho-SV2A S42,
45, and 47 (S686D, third bleed; raised against residues 36–54 of human
SV2A: CKKRVQDEYpSRRpSYpSRFEEEDDKK). Anti-SV2A (ab32942)
and anti-GST [horseradish peroxidase (HRP); ab58626] antibodies were
purchased from Abcam, and anti-synaptotagmin-1 (catalog #3347) was
from Cell Signaling Technology. Secondary antibodies coupled to HRP
were obtained from Thermo Fisher Scientific.
Identification of phosphorylation sites. HEK293 cells were transfected
with a construct encoding WT and the indicated mutants of full-length
Flag–SV2A. Thirty-six hours after transfection, cells were lysed, and
Flag–SV2A was purified by immunoprecipitation and incubated with
recombinant WT TTBK2[1–316] or kinase inactive (KD) TTBK2[D163A,
1–316] andMg2–[- 32P]ATP for 60 min. Samples were subjected to elec-
trophoresis on a polyacrylamide gel that was stained with colloidal Coo-
massie blue and autoradiographed. Phosphorylated SV2A was digested
with trypsin, and the peptides were separated on a reverse-phase HPLC
Vydac C18 column (catalog #218TP5215; Separations Group) equili-
brated in 0.1% (v/v) trifluoroacetic acid, and the column developed with
a linear acetonitrile gradient at a flow rate of 0.2 ml/min. Fractions (0.1
ml each) were collected and analyzed for 32P radioactivity by Ceren-
kov counting. Phosphopeptides were analyzed by liquid chroma-
tography (LC)-MS/MS using a Thermo U3000 RSLC nano liquid
chromatography system (Thermo Fisher Scientific) coupled to a Thermo
LTQ-OrbitrapVelosmass spectrometer (ThermoFisher Scientific). Data
files were searched using Mascot (www.matrixscience.com) run on an
in-house system against a database containing the appropriate SV2A
sequences, with a 10 ppm mass accuracy for precursor ions, a 0.6 Da
tolerance for fragment ions, and allowing for Phospho (ST), Phospho
(Y), Oxidation (M), and Dioxidation (M) as variable modifications. In-
dividual MS/MS spectra were inspected using Xcalibur 2.2 (Thermo
Fisher Scientific), and Proteome Discoverer with phosphoRS 3.1
(Thermo Fisher Scientific) was used to assist with phosphosite assign-
ment. The site of phosphorylation of 32P-labeled peptides was deter-
mined by solid-phase Edman degradation on a Shimadzu PPSQ33A
Sequencer of the peptide coupled to Sequelon-AA membrane (Applied
Biosystems) as described previously (Campbell and Morrice, 2002). The
above LC-MS/MS approach was also used for the analysis of phospho-
sites on mouse brain SV2A (Table 1) and on WT and mutant SV2A
overexpressed in HEK293 cells (Table 2).
Isothermal titration calorimetry. Binding of SV2A peptides to
synaptotagmin-1 was assayed by isothermal titration calorimetry (ITC)
Zhang et al. • SV2A Phosphorylation Controls Synaptotagmin Traffic J. Neurosci., February 11, 2015 • 35(6):2492–2507 • 2493
Table 2. Identification of phosphorylation sites on wild-type andmutant SV2A overexpressed in HEK293 cells
Peptides identified by mass spectrometry Mass Mascot score Possible P sites % Probability (PD1.4 pRS3.1)
SV2AWT
150–250 kDa
R.GGLSDGEGPPGGR.G P (ST) 1234.4970 79 S127 100
K.TIHQEDELIEIQSDTGTWYQR.W P (ST) 2641.1762 21 S411 99
R.SYSRFEEEDDDDDFPAPSDGYYR.G P (ST) 2854.0594 42 Either S45 or Y46 or S47 33, 33, 33
R.GEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A P (ST) 3950.5028 72 Either S80 or S81 49, 49
R.GEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A 2 P (ST) 4030.4774 54 S80, T84, (S81) 86, 97, (16)
R.GEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A 3 P (ST) 4110.4389 47 S80, S81, T84 100, 100, 100
75–150 kDa
R.VFSVTHIK.T P (ST) 1009.4900 30 Either S393 or T395 50, 50
R.GGLSDGEGPPGGR.G P (ST) 1234.4972 83 S127 100
K.TIHQEDELIEIQSDTGTWYQR.W P (ST) 2641.1706 36 S411 99
R.SYSRFEEEDDDDDFPAPSDGYYR.G P (ST) 2854.0568 47 Either S45 or Y46 or S47 33, 33, 33
R.RSYSRFEEEDDDDDFPAPSDGYYR.G P (ST) 3010.1636 76 S45 99
R.GEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A P (ST) 3950.5028 101 S81, (S80) 84, (14)
R.GEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A 2 P (ST) 4030.4763 58 Either of S80, S81 and T84 53, 53, 92
R.GEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A 3 P (STY) 4110.4447 60 S80, S81, T84 100, 100, 100
R.GEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A 4 P (STY) 4190.4062 26 T71, S80, S81 100, 100, 100, 100
SV2A T84A
150–250 kDa
R.GGLSDGEGPPGGR.G P (ST) 1234.4978 63 S127 100
R.SYSRFEEEDDDDDFPAPSDGYYR.G P (ST) 2854.0609 24 Either S45 or Y46 or S47 33, 33, 33
R.GEGTQDEEEGGASSDAAEGHDEDDEIYEGEYQGIPR.A P (STY) 3920.4970 64 Either S80 or S81 50, 50
R.GEGTQDEEEGGASSDAAEGHDEDDEIYEGEYQGIPR.A 2 P (STY) 4000.4665 56 S80, S81 100, 100
R.GEGTQDEEEGGASSDAAEGHDEDDEIYEGEYQGIPR.A 3 P (STY) 4080.4425 45 T71, S80, S81, T84 100, 100, 100
75–150 kDa
R.VFSVTHIK.T P (ST) 1009.4989 22 Either S393 or T395 50, 50
R.GGLSDGEGPPGGR.G P (ST) 1234.4968 56 S127 100
R.SYSRFEEEDDDDDFPAPSDGYYR.G P (ST) 2854.0609 45 Either S45 or Y46 or S47 33, 33, 33
R.RSYSRFEEEDDDDDFPAPSDGYYR.G P (ST) 3010.1631 51 S45 99
R.GEGTQDEEEGGASSDAAEGHDEDDEIYEGEYQGIPR.A P (ST) 3920.5014 90 S81, (S80) 87, (13)
R.GEGTQDEEEGGASSDAAEGHDEDDEIYEGEYQGIPR.A 2 P (STY) 4000.4705 58 S80, S81 100, 100
R.GEGTQDEEEGGASSDAAEGHDEDDEIYEGEYQGIPR.A 3 P (STY) 4080.4261 57 T71, S80, S81 100, 100, 100
SV2A S80, S81A
150–250 kDa
R.GGLSDGEGPPGGR.G P (ST) 1234.4972 57 S127 100
K.TIHQEDELIEIQSDTGTWYQR.W P (ST) 2641.1698 37 S411 100
R.SYSRFEEEDDDDDFPAPSDGYYR.G P (ST) 2854.0585 46 Either S45 or Y46 or S47 33, 33, 33
75–150 kDa
R.GGLSDGEGPPGGR.G P (ST) 1234.4972 60 S127 100
K.TIHQEDELIEIQSDTGTWYQR.W P (ST) 2641.1697 57 S411 100
R.SYSRFEEEDDDDDFPAPSDGYYR.G P (ST) 2854.0555 69 Either S45 or Y46 or S47 33, 33, 33
HEK293 cells were transfected with a construct encoding full-length WT or indicated mutant of Flag–SV2A. Thirty-six hours after transfection, cells were lysed and Flag–SV2A immunoprecipitated from 4 mg of cell extract, and the
immunoprecipitates were electrophoresed on a polyacrylamide gel. After colloidal Coomassie blue staining, the bands corresponding to SV2Awere excised and digested with trypsin. Phosphorylated peptides were identified by LC-MS/MS
analysis. The data analysis was as in Materials and Methods. The sequence of each peptide is shown with possible phosphorylation sites underlined. Also shown are the mass of the peptide, the Mascot score of the peptide identification,
in which individual ion scores17 indicate identity or extensive homology ( p 0.05), and the percentage probability of the phosphosite assignment, as determined by the phosphoRS 3.1 component of the Proteome Discoverer 1.4
software.
Table 1. Identification of phosphorylation sites onmouse brain SV2A
Peptides identified by mass spectrometry Mass Mascot score Possible P sites % Probability (PD1.4 pRS3.1)
150 kDa
R.GGLSDGEGPPGGR.G P (ST) 1234.4310 64 S127 100
R.GGLSDGEGPPGGRGEAQR.R P (ST) 1775.6966 35 S127 100
R.GEGAQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A 2 P (ST) 4000.3955 66 S80, 81 98, 98
R.GEGAQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A 3 P (ST) 4080.3606 32 S80, S81, T84 100, 100, 100
75–150 kDa
R.VFSVTHIK.T P (ST) 1009.4332 44 S393 99
R.GGLSDGEGPPGGR.G P (ST) 1234.4322 72 S127 100
R.GGLSDGEGPPGGRGEAQR.R P (ST) 1775.6939 50 S127 100
R.GEGAQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A P (ST) 3920.4297 90 S81 88
R.GEGAQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A 2 P (ST) 4000.3966 60 S81 and either of S80 or T84 53, 92, 53
R.GEGAQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR.A 3 P (ST) 4080.3698 66 S80, S81, T84 100, 100, 100
Endogenous SV2Awas immunoprecipitated frommousebrain extract (8mg). The immunoprecipitateswere electrophoresedonapolyacrylamidegel, andafter Colloidal blue staining, bands corresponding to SV2Awere excised anddigested
with trypsin. Phosphorylated peptides were identified by LC-MS/MS analysis. The data analysis was as in Materials and Methods. The sequence of each peptide is shown with possible phosphorylation sites underlined. Also shown are the
mass of the peptide, the Mascot score of the peptide identification, in which individual ion scores21 indicate identity or extensive homology ( p 0.05), and the percentage probability of the phosphosite assignment, as determined
by the phosphoRS 3.1 component of the Proteome Discoverer 1.4 software.
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using a VP-ITC microcalorimeter (MicroCal). Unphosphorylated or
phosphorylated peptides (0.8 mM) of SV2A (residues 76–90) were
titrated into synaptotagmin-1 C2B domain (residues 270–422, 0.04
mM), and enthalpic changes for each injection (5l) were recordedwhile
stirring at 300 rpm at a constant temperature of 25°C for 180 s. Injections
were performed until a molar peptide/protein ratio of at least 2.5:1 was
reached. The integrated binding isotherms for each injection were ob-
tained from the enthalpic changes versus the ratios between peptide con-
centration and total protein concentration using data analysis software
Origin 7.0 (including MicroCal add-on; OriginLab). Single or multiple
independent site models were then fitted to the data by nonlinear regres-
sion inOrigin 7.0 with theMicroCal ITC patch installed. Themodel with
the lowest  2 fit by least-squares analysis was used to obtain the Kd
apparent. The first injection (2 l) was excluded from the analysis. In all
cases, an independent single sites model provided the best fit with an
overall stoichiometry of 1 0.3.
Protein purification and crystallization of synaptotagmin-1C2B domain.
Recombinant human synaptotagmin-1 C2B domain (residues 270–422)
was overexpressed in E. coli BL21 (DE3; Studier and Moffatt, 1986) with
an N-terminal GST tag and TEV-protease cleavage site from construct
DU number 44151 (MRC–PPU). Bacterial cells were grown in 50 ml of
Luria–Bertani (LB) broth supplemented with 100 mg/ml ampicillin
(Amp) at 37°C for 16 h and subsequently used to inoculate 950 ml of LB
broth (with Amp) in baffled 2 L flasks. Cultures were grown at 37°C for
	5 hwith vigorous shaking at 180 rpmuntil an optical density of	0.6 at
600 nmwas reached, and overexpression was subsequently induced with
0.25 mM isopropyl -D-1-thiogalactopyranoside at 19°C for 16 h. Bacte-
rial cells were harvested by centrifugation at 5000
 g and 4°C for 15min,
and the cell pellet was resuspended in 50mMHEPES, pH7.5, and 250mM
NaCl, supplemented with protease inhibitor cocktail (Calbiochem).
Cells were lysed by freeze–thawing at80°C, followed by sonication on
ice, and the cell extract was cleared from intact cells and debris by cen-
trifugation at 30,000
 g and 4°C for 20 min.
GST-tagged protein was purified by affinity chromatography in a
16/20 XK column (GE Healthcare) packed with 10 ml of glutathione
Sepharose 4B (GE Healthcare) in 50 mM HEPES, pH 7.5, and 250 mM
NaCl, and bound protein was eluted with 40mM reduced glutathione, 50
mMHEPES, pH 7.5, and 250mMNaCl. Purified protein was cleaved with
TEV protease (DU6811; MRC–PPU) in 50 mM HEPES, pH 7.5, 250 mM
NaCl, and 40mM reduced glutathione on ice overnight and subsequently
desalted and eluted into 50 mM HEPES, pH 7.5, using a HiPrep 26/10
desalting column (GE Healthcare). Cleaved protein was further purified
by ion exchange chromatography using a 16/20 XK column packed with
10 ml of Source 15S matrix (GE Healthcare), which was equilibrated in
50mMHEPES, pH 7.5, and bound protein was eluted in a linear concen-
tration gradient from 0 to 50% in five column volumes of 50mMHEPES,
pH 7.5, and 1 M NaCl. Fractions containing cleaved synaptotagmin-1
C2B domain fragment were finally purified by size exclusion chromatog-
raphy in a HiLoad 16/600 Superdex 200 PG column (GE Healthcare) in
50 mM HEPES, pH 7.5, and 50 mM NaCl. Protein purity and quality was
monitored by SDS-PAGE, followed by staining with Coomassie Brilliant
Blue, and protein concentration was estimated with a NanoDrop pho-
tospectrometer (Thermo Fisher Scientific) using the theoretical ex-
tinction coefficient and molecular mass of the protein sequence using
the PROTPARAM web server (Gasteiger et al., 2005).
Purified human synaptotagmin-1 C2B domain (residues 270–422)
was crystallized with the synthetic peptide of SV2A (residues 76–90),
which was phosphorylated at Thr84. Commercially available crystalliza-
tion screens were used to find preliminary conditions for protein crystal-
lization, and a Mosquito Crystal liquid handling robot (TTP Labtech)
was used to spot 0.2 l of protein/peptide solutions (molar ratio of 1:3)
and 0.2 l of reservoir solution into 96-well MRC plates (Hampton
Research). Initial protein crystals were obtained by sitting drop vapor
diffusion at 291 K in Index HT, Crystal Screen HT, and PEG/Ion HT
crystallization screens (HamptonResearch) andwere subsequentlyman-
ually optimized. Final crystallization using hanging-drop vapor diffusion
at 291 Kwas set up by co-crystallizing 0.5mM synaptotagmin-1 C2Bwith
1.4 mM SV2A peptide [EGGASSDA(pT)EGHDED], which was com-
bined with reservoir solution consisting of 0.1 M HEPES, pH 7.5, 18%
polyethylene glycol (PEG) 3350, and 50 mM CaCl2 in a 1:1 ratio.
x-Ray data collection and structure determination and refinement
crystals were soaked in 25% glycerol, 20%PEG 3350, 100mM, and 50mM
CaCl2 for 5 min and flash frozen in liquid nitrogen. Diffraction data was
obtained at 100 K using a Rigaku MicroMax-007 rotating anode x-ray
generator (1.54 A(Angstrom)) coupled to a Saturn 944 CCD detector
and processed using the XDS program package (Evans, 2006). Diffrac-
tion images of two reflection sets from one crystal were scaled and
merged using Aimless version 0.2.17, and Laue groups were determined
with Pointless version 1.8.17 (Evans and Murshudov, 2013) within the
CCP4 program suite (Kabsch, 2010). The crystals were packed in the
monoclinic space group P1211 and crystallized to 1.87 Å resolution,
whichwas cut to 1.95 Å to obtain90% completeness for the outer shell.
The synaptotagmin-1 C2B domain structure was solved using PHENIX
Phaser version 2.5.5 (McCoy et al., 2007) bymolecular replacement with
Protein Data Bank (PDB) entry 1TJX (Cheng et al., 2004) as input tem-
plate. The model was refined by iterative operations using PHENIX Re-
fine version 1.8.3 (Adams et al., 2010) in combination with manual
model building in COOT (Emsley andCowtan, 2004). Residues 81–90 of
the SV2A peptide and solvent molecules were added manually to the
model according to electron- and difference-density maps. A difference
map of the Apo protein of Syt1 was created in Phenix Refine after initial
refinements without the SV2A peptide chain included in the model.
Illustrations were prepared with PyMol (http://www.pymol.org/), and
electrostatics representations were calculated using the APBS plugin
(Baker et al., 2001).
Fluorescence polarization. Binding of SV2A peptide phosphorylated at
residue Thr84 to synaptotagin-1 C2B domain mutants with lysine-to-
alanine substitutions K314A, K326A, K328A, or K326A/K328A was
tested by fluorescence polarizationmeasurements. SV2A peptides corre-
sponding to residues 76–90 were designed with a N-terminal tetra-
cysteine motif and either synthesized without phosphorylation (CCP
GCCGGGEGGASSDATEGHDED) or phosphorylated at Thr84 [CCP
GCCGGGEGGASSDA(pT)EGHDED] (Pepceuticals). Peptides were
labeled with FlAsH–EDT2 [4,5-bis(1,3,2-dithioarsolan-2-yl)fluores-
cein-(1,2-ethanedithiol); Griffin et al., 1998] at the tetra-cysteine motif
by incubating 0.02 mM peptide with 0.04 mM FlAsH–EDT2 in a final
volume of 0.5 ml of 50 mM HEPES–NaOH, pH 7.5, and 50 mM NaCl at
room temperature for 2 h. Labeled peptides were dialyzed against 50 mM
HEPES–NaOH, pH 7.5, and 50 mM NaCl at 4°C for 24 h and protected
from light.
For fluorescence polarization assays, 0–20 M protein of synaptotagmin-1
C2B domain (residues 270–422) was titrated into 0.1 M FlAsH-labeled
peptide in 30 l of 50 mM HEPES–NaOH, pH 7.5, and 50 mM NaCl in
black 384-well assay plates (Corning). Fluorescence polarization was
monitored at 485 nm excitation and 520 nm emission using a Pherastar
FS plate reader (BMG Labtech) and plotted against synaptotagmin-1
C2B concentration. A nonlinear one-site binding model with Hill slope
was fitted to the data points using analysis software Prism 6 (GraphPad
Software).
Hippocampal neuronal cultures.Dissociated primary hippocampal en-
riched neuronal cultureswere prepared frombothmale and female E17.5
C56BL/6J mouse embryos by trituration of isolated hippocampi to ob-
tain a single-cell suspension, whichwas plated at a density of 5
 105 cells
per coverslip on poly-D-lysine and laminin-coated 25 mm coverslips.
Cultures were maintained in Neurobasal media supplemented with
B-27, 0.5 mM L-glutamine, and 1% v/v penicillin/streptomycin. After
72 h, cultures were further supplemented with 1 M cytosine -D-
arabinofuranoside to inhibit glial proliferation. Cells were transfected
after 7–8 d in culture with Lipofectamine 2000 as described previously
(Gordon et al., 2011). In all experiments, two constructs were coex-
pressed; either Syt1–pHluorin or synaptophysin–pHluorin was cotrans-
fected with either mCer empty vector or mCer–pSUPER shRNA vectors.
In addition,mCer–SV2Awas coexpressedwith a pSUPER shRNAvector,
which expressed Syt1–pHluorin. Neurons were imaged after 13–16 d in
culture.
Immunolabeling. Immunolabeling of transfected cultured hippocam-
pal neuronswas performed as described previously (Gordon et al., 2011).
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Syt1–pHluorin expression was visualized at 480 nm, whereas SV2A ex-
pression was visualized at 550 nm. Identically sized regions of interest
were placed over transfected Syt1–pHluorin puncta and nontransfected
puncta in the same field of view, along with background regions. The
level of SV2A expression was calculated by subtracting background au-
tofluorescence before rationing transfected/nontransfected SV2A ex-
pression levels.
Fluorescent imaging of pHluorin trafficking. Hippocampal cultures
were mounted in a Warner imaging chamber with embedded parallel
platinum wires (RC-21BRFS) and placed on the stage of Zeiss Axio Ob-
server D1 epifluorescence microscope. Neurons transfected with mCer
vectors were visualized with a Zeiss Plan Apochromat 40
 oil-
immersion objective (numerical aperture 1.3) at 430 nm excitation,
whereas pHluorin reporters were visualized at 500 nm (both using a
dichroic filter 525 nm and long-pass emission filter 535 nm). Cul-
tures were stimulated with a train of 300 action potentials delivered at 10
Hz (100 mA, 1 ms pulse width). Cultures were subjected to continuous
perfusion at room temperature (23°C) with imaging buffer (136 mM
NaCl, 2.5 mM KCl, 2 mM CaCl2, 1.3 mM MgCl2, 10 mM glucose, and 10
mMHEPES,pH7.4, supplementedwith10M6-cyano-7-nitroquinoxaline-
2,3-dione and 50MDL-2-amino-5-phosphonopentanoic acid). After stim-
ulation, cultures were then challenged with alkaline imaging buffer (50 mM
NH4Cl substituted for 50 mM NaCl) to reveal total pHluorin fluorescence.
Fluorescent images were captured at 4 s intervals using a Hamamatsu
Orca-ER digital camera and processed offline using NIH Image J 1.43
software. Regions of interest of identical size were placed over nerve
terminals, and the total fluorescence intensity was monitored over time.
Only regions that responded to action potential stimulation were se-
lected for analysis. All statistical analyseswere performedusingMicrosoft
Excel and Prism software (GraphPad Software). The pHluorin fluores-
cence change was calculated as F/F0.
Surface fraction of Syt1–pHluorin. Estimation of surface Syt1–pHluo-
rin was performed by perfusing acidic imaging buffer (substituting 20
mM MES for HEPES, pH 5.5) over cultures for 30 s (to quench surface
Syt1–pHluorin), followed by a 1 min perfusion with imaging buffer, pH
7.4. Cultures were then subjected to alkaline imaging buffer for 30 s to
reveal total Syt1–pHluorin. The surface fraction of Syt1–pHluorin as a
percentage of total was estimated using the following equation: (neutral
fluorescence  acidic fluorescence/alkali fluorescence  acidic fluores-
cence)
 100.
Statistical analysis. In all cases, n refers to the number of independent
experiments performed. All statistical analyses were performed using
Prism software (GraphPad Software), and all data were tested by Stu-
dent’s t test with the exception of pHluorin time course experiments
(two-way ANOVA) and Syt1–pHluorin surface expression during SV2A
knockdown (one-way ANOVA).
Results
CK1 family kinases phosphorylate SV2A at two clusters
of sites
The CK1 group of eukaryotic protein kinases are composed of
seven CK1 isoforms (CK1, CK12, CK1, CK1, CK11,
CK12, and CK13), two Tau–tubulin kinase isoforms (TTBK1
and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3;
Manning et al., 2002). We compared the ability of CK1 isoforms
(CK11, CK1, CK1, andCK11), TTBK isoforms (TTBK1 and
TTBK2), and VRK1 to phosphorylate a fragment of SV2A[1–
160] that encompasses the cytoplasmic domain that previous
work has suggested represents the region that CK1 phosphory-
lates (Pyle et al., 2000). Moreover, as mentioned in the Introduc-
tion, global phosphorylation site analysis has indicated that SV2A
is phosphorylated at numerous sites within its N-terminal 160
residue domain (http://www.phosphosite.org/proteinAction.
do?id8509& showAllSitestrue). We observed that, under
conditions used, all CK1 and TTBK2 isoforms tested phosphor-
ylated SV2A[1–160] to different extents (Fig. 1). A recombinant
fragment of TTBK2 encompassing its catalytic domain (residues
1–316) phosphorylated SV2A[1–160] to the highest stoichiome-
try, followed by CK1, TTBK1, and CK1. CK11 and CK11
phosphorylated SV2A[1–160] 10-fold less efficiently than
TTBK2[1–316] (Fig. 1). Recombinant VRK1 failed to phosphor-
ylate SV2A[1–160] in parallel experiments, although it was
judged active because it was capable of autophosphorylation
(Fig. 1).
To map the phosphorylation sites on SV2A, we used full-
length SV2A isolated from a HEK293 cell overexpression system,
using TTBK2[1–316] that our in vitro studies suggested was the
most efficient CK1 family kinase at phosphorylating SV2A in
vitro. Consistent with data shown in Figure 1, we found that WT
but not a kinase-inactive fragment of TTBK2 phosphorylated
full-length SV2A (Fig. 2A). TTBK2[1–316] 32P-phosphorylated
full-length SV2A was digested with trypsin, and the resultant
tryptic peptides were analyzed by chromatography on a C18 col-
umn (Fig. 2B). The major 32P-labeled phosphopeptides were
subjected tomass spectrometry and solid-phase Edman sequenc-
ing to identify the phosphorylation sites. This analysis resulted in
the identification of 8 phosphorylation sites (Ser42, Ser45, Ser47,
Ser62, Ser80, Ser81, Thr84 and Ser127; Fig. 2C). These phosphor-
ylation sites are all located within the N-terminal 160 residue
cytoplasmic domain of SV2A (Fig. 2D). Sequence alignment in-
dicates that the evolutionary conserved CK1 phosphorylation
sites on SV2A lie within two constellations that we have termed
here Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80,
Ser81, and Thr84). The nonconserved Ser62 and Ser127 residues
lie outside these clusters (Fig. 2E). Mutation of all eight phos-
phorylation sites on the full-length SV2A abolished phosphory-
lation by TTBK2[1–316] (Fig. 2A). We were also able to monitor
phosphorylation of SV2A by TTBK2[1–316] using phosphospe-
cific antibodies thatwe generated that recognize SV2A after phos-
phorylation of either Cluster-1 or Cluster-2 residues (Fig. 2A).
This revealed that full-length SV2A isolated from HEK293 cells
was detectably phosphorylated at Cluster-2 but not Cluster-1.
After incubation with WT but not kinase-inactive TTBK2[1–
316], phosphorylation of Cluster-1 sites became detectable and
phosphorylation of Cluster-2 sites markedly increased.
We also compared the ability of TTBK and CK1 isoforms to
phosphorylate mutants of SV2A[1–160] in which Cluster-1
(Ser42, Ser45, and Ser47) and/or Cluster-2 (Ser80, Ser81, and
Thr84) residues are mutated to Ala to ablate phosphorylation.
These studies revealed that all CK1 family kinases tested phos-
phorylated SV2A[1–160] at both Cluster-1 and Cluster-2
residues to differing extents, because phosphorylation of SV2A
[1–160] was significantly suppressed after mutation of either
Cluster-1 or Cluster-2 (Fig. 1). Moreover, mutation of both
Cluster-1 and Cluster-2 residues virtually abolished phosphory-
lation of SV2A by this group of kinases, indicating that these sites
do indeed comprise the major phosphorylation sites by the CK1
family.Wewere also able tomonitor phosphorylation of SV2Aby
CK1 and TTBK isoforms that phosphorylated SV2A to the high-
est stoichiometry by using phosphospecific antibodies that we
generated that recognize SV2A after phosphorylation of either
Cluster-1 or Cluster-2 residues (Fig. 1).
Phosphorylation of SV2A at Ser80/Ser81 and Thr84 in vivo
We next analyzed the phosphorylation of SV2A in vivo. Endoge-
nous SV2A immunoprecipitated frommouse brain was resolved
in SDS-PAGE (data not shown) from which two major bands
corresponding to SV2A were excised and subjected to mass spec-
trometry analysis (one band migrated beyond 150 kDa maker,
whereas the other was between the 75 and 100 kDa markers).
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Peptides matching mouse SV2A sequence were identified from
both excised bands, indicating these two distinguishable bands
from SDS-PAGE correspond to SV2A. The significant mass dif-
ference between the product ions frommodified and unmodified
peptides (data not shown) allowed us to identify the phosphory-
lated peptides from SV2A (Table 1). Other than Ser393, all of the
identified phosphorylation sites (Table 1) accumulated in the
N-terminal cytoplasmic region (residue 1–169) of SV2A, pre-
dominantly in the Cluster-2 phosphorylation sites (Fig. 1).
CK1 isoforms are known to preferentially phosphorylate a
Ser/Thr residue in a protein that is “primed” by previous phos-
phorylation at the 3 position (corresponding to Ser81 relative
to Thr84 in SV2A; Flotow et al., 1990). In addition, a4 position
acidic or phosphorylated residue (corresponding to Ser80 rela-
tive to Thr84 in SV2A) has also been reported to facilitate phos-
phorylation (Meggio et al., 1991). Therefore, it is possible that
phosphorylation of Ser80/Ser81might prime phosphorylation of
Thr84. To test this possibility in vivo, we overexpressed WT or
Ser/Thr to Ala mutant SV2A in HEK293 cells and assessed their
phosphorylation state. As shown in Table 2, similar to what was
observed in mouse brain extract, WT SV2A was phosphorylated
at the Cluster-2 sites (Ser81, Ser82, and Thr84; Table 2), vali-
Figure 1. CK1 family members phosphorylate the N-terminal cytoplasmic domain of SV2A. The indicated CK1 family kinases (TTBK2[1–316], TTBK1[1–1321, full length], VRK1[1–396,
full length], CK11[1–337, full length], CK1[1– 415, full length], CK1[1– 416, full length], and CK11[1– 422, full length]) were all expressed in E. coliwith the indicated N-terminal
GST or MBP tag. The kinases were incubated at a final concentration of 0.5Mwith 2mMMg 2, 0.1mM- 32P[ATP], and 5MWT SV2A[1–160] or indicated SV2Amutants in which either
Cluster-1 (Ser42, Ser45, and Ser47; termed C1 Mutant) and/or Cluster-2 (Ser80, Ser81, and Thr84; termed C2 Mutant) phosphorylation sites were mutated to Ala to prevent phosphor-
ylation. Reactions were left to proceed for 30 min at 30°C, subjected to electrophoresis on a polyacrylamide gel, stained with colloidal Coomassie blue, and autoradiographed. The
Coomassie blue-stained SV2A[1–160] band was excised, and 32P incorporation was assessed by Cerenkov counting. Relative phosphorylation of WT SV2A[1–160] by CK1 family kinases
is indicated in the table. Reactions were also subjected to immunoblot analysis with the indicated phospho-specific antibodies that recognize phosphorylated Cluster-1 or Cluster-2 sites.
All data are representative of at least two independent experiments.
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Figure 2. Identification of TTBK2 phosphorylation sites on SV2A. A, HEK293 cells were transfected with a construct encoding WT Flag–SV2A or a mutant Flag–SV2A in which all eight
phosphorylation sites identified inC, namely Ser42, Ser45, Ser47, Ser62, Ser80, Ser81, Thr84, and Ser127, aremutated toAla [termed8
 S(T)/A]. Thirty-six hours after transfection, cellswere lysed,
andWTandmutant Flag–SV2Awas immunoprecipitated and incubatedwith recombinantWTTTBK2[1–316] or kinase inactive (KD) TTBK2[D163A, 1–316] andMg 2–[- 32P]ATP for 60min. Samples
were subjected to electrophoresis on a polyacrylamide gel that was stained with colloidal Coomassie blue and autoradiographed. Reactions were also (Figure legend continues.)
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dating the utility of this overexpression system for studying
SV2A phosphorylation in vivo. More importantly, no phos-
phorylated peptide covering Thr84 was identified in the absence
of phosphorylation on either Ser80 or Ser81, whereas absence of
phosphorylation of Thr84 had no significant effect on the phos-
phorylation of Ser80 and Ser81. Mutation of Ser80 and Ser81 to
Ala also prevented phosphorylation of Thr84.
Cluster-2 phosphorylation promotes the ability of SV2A to
bind synaptotagmin-1
To explore whether CK1-mediated phosphorylation of SV2A
directly controlled its association with other protein(s), we gen-
erated biotinylated peptides that encompassed either the dephos-
phorylated or triply phosphorylated Cluster-1 (Ser42, Ser45, and
Ser47) or Cluster-2 (Ser80, Ser81, and Thr84) residues of SV2A.
These were conjugated to streptavidin–Sepharose and used in
affinity purification studies to identify protein(s) that associated
with the phosphorylated but not dephosphorylated peptides in
mouse brain extract.Mass spectrometry analysis revealed that the
major hit that associated with the phosphorylated peptide to a
much greater extent than the dephosphorylated Cluster-2 pep-
tide are the highly related synaptotagmin-1 and synaptotagmin-2
proteins. As mentioned in the Introduction, synaptotagmin-1
interacts with SV2A through its N-terminal domain (Schivell et
al., 1996, 2005; Lazzell et al., 2004; Fig. 3A). Immunoblot analysis
confirmed that synaptotagmin-1 interacted with the Cluster-2
phosphorylated peptide but not with the dephosphorylated pep-
tide (Fig. 3B). No clear-cut specific interactors to the Cluster-1
peptide were identified in parallel experiments (data not shown).
To obtain additional evidence that the interaction between
SV2A and synaptotagmin-1 was promoted by phosphorylation,
we immunoprecipitated SV2A frommouse brain and treated the
immunoprecipitates in the presence or absence of lambda phos-
phatase. This revealed that treatment with lambda phosphatase
lowered the level of synaptotagmin-1 associated with immu-
noprecipitated SV2A, and this effect was blocked by the addi-
tion of EDTA, which inhibits lambda phosphatase catalytic
activity (Fig. 3C).
Phosphorylated Cluster-2 SV2A peptide interacts with
synaptotagmin-1 C2B domain
Human synaptotagmin-1 is a 422 residue protein possessing a
transmembrane membrane region at the N terminus (residues
58–80) that anchors it to SV membranes, which is followed by
two Ca2-binding C2 domains termed C2A (residues 157–245)
and C2B (residues 287–382). Synaptotagmin-1 operates as the
key Ca2 sensor in SV trafficking and neurotransmitter release at
the synapse (Brose et al., 1992; Geppert et al., 1994). To establish
which region of synaptotagmin-1 interacts with the phosphory-
lated Cluster-2 peptide, we expressed fragments of synapto-
tagmin-1 and tested their ability to interact with biotinylated
phosphorylated Cluster-2 peptide. This revealed that a fragment
encompassing isolated C2B domain interacted robustly with the
phosphorylated Cluster-2 peptide under conditions in which
fragments lacking the C2B domain failed to bind (Fig. 3D).
We next performed isothermal calorimetric-binding analysis
to assess the interaction of the isolated synaptotagmin-1 C2B
domain (residues 270–422) with different combinations of
Cluster-2 phosphorylated residues (Ser80, Ser81, and Thr84; Fig.
4). This revealed that the key phosphorylation site mediating
binding between the SV2A C2B domain and synaptotagmin-1
was Thr84. The Cluster-2 peptide phosphorylated only at Thr84
interacted with synaptotagmin-1 C2B domain with high affinity
(Kd of 	300 nM), whereas all peptides phosphorylated at Ser80
and/or Ser81, but not Thr84, failed to bind to the synapto-
tagmin-1 C2B domain. SV2A peptides phosphorylated at Thr84
aswell as Ser80 and/or Ser81 also interactedwith theC2Bdomain
of synaptotagmin-1, but the binding affinities were lower than
with the peptide phosphorylated at Thr84 alone (Fig. 4). In addi-
tion, phosphorylation at Ser81 together with phosphorylated
Thr84 seems to decrease the enthalpic nature of the interaction,
and this may indicate a destabilizing effect on binding of the
phosphorylation at Ser81. This destabilizing effect was also re-
flected in an increased binding entropy of peptides phosphory-
lated at pSer81 pThr84 and pSer80 pSer81 pThr84, which
was estimated at 	20 cal  mol1  K1. We also calculated the
dissociation constant of the interactions, and the peptide phos-
phorylated at pSer81 pThr84 had a higherKd of	900 nM than
the peptide phosphorylated at pSer80  pThr84. However, it
should be noted that the increased dependency on entropy in the
interaction between synaptotagmin-1 and peptides containing
phosphorylated Ser81 increased the signal-to-noise ratio and
hence error in the calculated Kd. Thus, phosphorylation of SV2A
on Thr84 is both necessary and sufficient for its interaction with
the C2B domain of synaptotagmin.
Structure of Cluster-2 phosphorylated peptide bound to
synaptotagmin-1 C2B domain
To probe the mechanism by which phosphorylated SV2A binds
to synaptotagmin-1, we crystallized the Thr84 phosphorylated
Cluster-2 peptide (residues 76–90) with the C2B domain (resi-
dues 270–422) of synaptotagmin-1 (PDB entry 4v11; for crystal-
lographic statistics, see Table 3). This revealed that the C2B
domain adopted the same overall topology as the previously de-
scribed nuclear magnetic resonance (NMR; Fernandez et al.,
2001) and x-ray crystallography (Cheng et al., 2004; Honigmann
et al., 2013) structures, composed of two layers of antiparallel 
sheets, along with two short  helices (Fig. 5A). Electron density
of the Thr84 phosphorylated Cluster-2 peptide from residues
81–90 was clearly resolved, interacting with a positively charged
surface region of synaptotagmin-1 that has been referred to as
the “polybasic region” (Fernandez et al., 2001; Fig. 5B). The
phosphorylated Thr84 residue formed hydrogen bonds with
three highly conserved surface-exposed Lys residues on the
synaptotagmin-1 C2B domain (Lys314, Lys326, and Lys328; Fig.
5C). These Lys residues are distributed on two anti-parallel 
sheets and form a specific binding pocket that precisely accom-
modates the phosphorylated Thr84 residue (Fig. 5C). The impor-
tance of these residues is emphasized by the finding that
4
(Figure legend continued.) subjected to immunoblot analysis with the indicated phospho-
specific antibodies that recognizephosphorylatedCluster-1or Cluster-2 sites. It shouldbenoted
that a low level of unidentified kinase(s) copurifies with Flag–SV2A from HEK293 cells, which
phosphorylates it to a low level in the absence of TTBK2. B, Full-length Flag–SV2A was incu-
bated with WT TTBK2[1–316] in the presence of Mg 2–[- 32P]ATP for 60 min as in A. Phos-
phorylated SV2A was digested with trypsin, and peptides were separated by reverse-phase
HPLC on a C18 column. The peaks containing the
32P-labeled phosphopeptides aremarked as in
the subdivisions of C. C, Summary of themass spectrometry and solid-phase Edman sequencing
data obtained after analysis of the peak fractions. The deduced amino acid sequence of each
peptide is shown, and the deduced 32P-labeled site is indicated in red. Note that, as SV2A was
isolated from HEK293 cells, certain peptides are pre-phosphorylated by endogenous kinase(s).
D, Domain structure of SV2A with the position of eight residues phosphorylated by TTBK2
indicated. All numbering refers to the human sequence. E, Sequence alignment of the residues
of SV2A that encompass the TTBK2 phosphorylation sites from the indicated species. Residues
highlighted indicated in red comprise the phosphorylation sites.
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Figure 3. Phosphorylation of SV2A at Cluster-2 promotes the interaction with synaptotagmin-1. Biotinylated dephosphorylated or triply phosphorylated (Ser80, Ser81, and Thr84)
peptides that encompassed the Cluster-2 region of SV2A were conjugated to streptavidin–Sepharose and incubated in mouse brain extract. Peptide–streptavidin–Sepharose conjugates
were washed, electrophoresed, and analyzed by mass spectrometry (A) or immunoblot analysis with the indicated antibody (B). In A, proteins that were not present in the control biotin
sample are listed. We also excluded three proteins (40S protein S19, 40S ribosomal protein S7, and elongation factor 1- 1) that are known frequent contaminants of mass spectrometry
experiments (Mellacheruvu et al., 2013). MW, Molecular weight; SN, supernatant; PD, pull-down. C, Endogenous SV2A was immunoprecipitated from mouse brain extract, and the
immunoprecipitates were treated in the presence () or absence () of lambda phosphatase and/or EDTA that inhibits the activity of lambda phosphatase. The immunoprecipitates
were washed and subjected to immunoblot analysis with the indicated antibodies. IP, Immunoprecipitated; IB, immunoblot. D, Schematic representation of the domain architecture of
human synaptotagmin-1. To establish which region of synaptotagmin-1 interacts with the phosphorylated Cluster-2 peptide, we expressed in E. coli the indicated fragments of
synaptotagmin-1. These proteins were incubated with biotinylated dephosphorylated or triply phosphorylated peptides used in A conjugated to streptavidin–Sepharose. The peptide–
streptavidin–Sepharose conjugates were washed, electrophoresed, and subjected to immunoblot analysis with an anti-GST antibody. Similar results were obtained in at least two
separate experiments for all data shown in this figure.
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individual mutations of Lys314, Lys326, or Lys328 inhibited
binding of the Cluster-2 Thr84 phosphorylated peptide to the
synaptotagmin-1 C2B domain at least sixfold, with mutation of
Lys328 having the largest effect (Fig. 5D).Mutation of Lys326 and
Lys328 together reduced binding of the SV2A peptide with phos-
phorylatedThr84 to levels similar to the nonphosphorylated pep-
tide binding to WT synaptotagmin-1 (Fig. 5D).
Initially, we also crystallized the triply phosphorylated Ser80,
Ser81, and Thr84 Cluster-2 peptide (residues 76–90) with the
C2B domain (residues 270–421) of synaptotagmin-1 because
this peptide represented the phosphorylation status seen in the
previous mass spectrometry experiments. Similarly, as seen with
the peptide only phosphorylated at Thr84, electron density of
residues 82–90 was clearly resolved. However, no density was
observed for the Ser80 and Ser81 phosphorylated residues, also
indicating that these residues may be disordered in this structure
(data not shown).
Phosphorylation of SV2A at Cluster-2 does not affect
its trafficking
We next addressed whether Cluster-2 phosphorylation of SV2A
has a direct effect on its trafficking during action potential-
evoked SV recycling. We generated an SV2A–pHluorin fusion
protein by inserting the pH-sensitive GFP pHluorin into the in-
travesicular loop between the first and second transmembrane
domains. This manipulation has no detrimental effect on evoked
SV recycling (Kwon and Chapman, 2011). At neutral pH, the
GFP pHluorinmoiety is highly fluorescent, but its fluorescence is
quenched in an acidic environment. Therefore, SV2A–pHluorin
has little or no fluorescence when inside SVs (which have a pH of
	5.5). The fusion of SV2A–pHluorin-expressing SVs can be
viewed as an increase in fluorescence and retrieval of SV2A–
pHluorin from the plasma membrane as a subsequent decrease
(because SV endocytosis is the rate-limiting step rather than SV
acidification; Sankaranarayanan and Ryan, 2000).
Both WT (SV2AWT–pHluorin) and a triple mutant with all
Cluster-2 sites mutated to alanine (SV2AP-null–pHluorin) were
distributed in a punctate manner when expressed in neuronal
culture, indicating their localization to nerve terminals (Fig. 6A).
When transfected neurons were challenged with a train of 300
action potentials (10Hz), we observed no significant alteration in
the extent of the SV2AP-null–pHluorin response compared with
SV2AWT–pHluorin [maximal evokedF, reflective ofmobiliza-
tion of the recycling SV pool normalized to the total SV pool
(revealed by alkaline buffer), SV2AWT–pHluorin, 0.39  0.05;
SV2AP-null–pHluorin, 0.43  0.04; n  4 for each; p  0.52,
Student’s t test]. This indicates that SV exocytosis was unlikely to
be affected by expression of this reporter. There was also no
Figure4. Phosphorylationof Thr84of SV2A is critical inpromoting the interactionwith synaptotagmin-1.Quantitative ITC-bindingassay to assess the interactionof the isolated synaptotagmin-1
C2B domain (residues 270–422) with a peptide encompassing the Cluster-2 region of SV2A (residues 76–90) in which combinations of Ser80, Ser81, and Thr84were phosphorylated as indicated.
SV2A peptides (0.8 mM), with phosphorylated residues as indicated on top of each panel, were titrated into purified synaptotagmin-1 C2B domain (0.04 mM) at 25°C using a VP-ITC microcaloriter
(MicroCal). The titration thermogram representing enthalpic heat release in microcalories per second is shown at the top, and the integrated binding isotherms are shown at the bottom of each
panel. When applicable, the best-fit curve, reaction stoichiometry (N), and dissociation constant (Kd) were calculated. Similar results were obtained in at least two separate experiments for all data
shown in this figure.
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significant difference in the loss of fluorescence after action
potential stimulation (Fig. 6B), indicating that Cluster-2
phosphorylation has no direct effect on SV2A retrieval during
SV endocytosis.
Ablation of SV2A binding accelerates synaptotagmin-1
retrieval during SV endocytosis
We next examined whether Cluster-2 phosphorylation con-
trolled the trafficking of its phospho-dependent interaction part-
ner synaptotagmin-1. To achieve this, we examined the
trafficking of an Syt1–pHluorin reporter (Diril et al., 2006) that
cannot bind SV2A (Syt1[K326A/K328A]–pHluorin). Both WT
Syt1–pHluorin and Syt1[K326A/K328A]–pHluorin were tar-
geted to nerve terminals (Fig. 6C) and displayed a similar evoked
fluorescence increase when challenged with 300 action potentials
(10 Hz), indicating no obvious role for the SV2A interaction in
SV exocytosis (maximal evoked F, Syt1WT–pHluorin, 0.49 
0.02; Syt1[K326A/K328A]–pHluorin, 0.44  0.03; n  6 WT,
n  8 [K326A/K328A]; p  0.17 Student’s t test). Syt1[K326A/
K328A]–pHluorin displayed significant accumulation at the
plasmamembrane (percentage surface fraction, Syt1WT–pHluo-
rin, 30.6 1.9; Syt1[K326A/K328A]–pHluorin, 45.8 4.5; n 9
WT, n 6 [K326A/K328A]; p 0.004 Student’s t test), a pheno-
type characteristic of dysfunctional SV cargo retrieval during SV
endocytosis (Yao et al., 2010; Gordon et al., 2011; Koo et al., 2011;
Kononenko et al., 2013). However, we observed a significant ac-
celeration in activity-dependent Syt1[K326A/K328A]–pHluorin
retrieval when compared with Syt1WT–pHluorin (Fig. 6D). This
acceleration was not attributable to escape of Syt1[K326A/
K328A]–pHluorin from the immediate vicinity of the nerve termi-
nal, because identical kinetics were observed when a larger axonal
area was sampled out with nerve terminals (data not shown).
Phosphorylation of T84 on SV2Amodulates the kinetics of
synaptotagmin-1 retrieval
We next explored whether loss of SV2A would also accelerate
synaptotagmin-1 retrieval. We designed an shRNA vector that
coexpressed both Syt1WT–pHluorin and an oligonucleotide se-
quence published to knockdown SV2A expression (Dong et al.,
2006).When this shRNA vector was expressed in culture, endog-
enous SV2A levels were reduced by75% when compared with
empty vector (Fig. 7A; endogenous SV2A expression, 23.3 
2.2% of empty vector). SV2A knockdown had no significant ef-
fect on the size of the evoked Syt1WT–pHluorin response (max-
imal evoked F, empty shRNA vector, 0.42  0.04; SV2A
shRNA1, 0.49  0.05; n  6 empty, n  5 shRNA1; p  0.33
Student’s t test). In contrast, Syt1WT–pHluorin retrieval was ac-
celerated in neurons expressing SV2A shRNA compared with
those expressing empty shRNA vector (Fig. 7B), mimicking the
trafficking of Syt1[K326A/K328A]–pHluorin.
We next confirmed that overexpression of WT SV2A could
rescue Syt1WT–pHluorin retrieval kinetics in neurons ex-
pressing SV2A shRNA. To achieve this, shRNA-resistant SV2A
tagged with the fluorescent protein mCer (mCer–SV2A) was
coexpressed with our modified shRNA vector expressing both
SV2A oligonucleotides and Syt1WT–pHluorin. Coexpression of
shRNA-resistant mCer–SV2A both restored SV2A expression
(total SV2A expression, 231 32% of empty vector control) and
fully rescued Syt1WT–pHluorin retrieval kinetics (Fig. 7C). In
contrast, mCer–SV2A lacking the critical Cluster-2 Thr84 phos-
phorylatable residue required for synpatotagmin-1 binding failed
to rescue Syt1WT–pHluorin retrieval (Fig. 7C). The T84A
mCer–SV2A mutant also failed to restore plasma membrane
levels of Syt1WT–pHluorin to that observed with WT mCer–
SV2A (Fig. 7D).
Genomic deletion of the monomeric adaptor for synaptotag-
min, stonin 2, accelerates both Syt1WT–pHluorin retrieval and
SV endocytosis (Kononenko et al., 2013). Thus, ablation of the
SV2A–synaptotagmin-1 interaction may also have a global effect
on SV endocytosis. To test this, we determined the effect of SV2A
knockdown on a distinct SV cargo, synaptophysin, because this
SVprotein is absent fromSV2Aprotein complexes (Schivell et al.,
1996). Knockdown of SV2A had no effect on either the peak
fluorescent response (maximal evokedF, empty shRNA vector,
0.36  0.04; SV2A shRNA1, 0.32  0.04; n  7 empty, n  5
shRNA1; p  0.43, Student’s t test) or the retrieval kinetics of
synaptophysin–pHluorin (Fig. 7E). Thus, SV2Aphosphorylation
is specifically required for synaptotagmin-1 retrieval and not SV
endocytosis in general.
Discussion
CK1 isoforms phosphorylate SV2A at highly conserved sites
We demonstrate in vitro that four CK1 and two TTBK isoforms
phosphorylated the cytoplasmic N-terminal domain of SV2A[1–
160] at two regions termed Cluster-1 (Ser42, Ser45, and Ser47)
and Cluster-2 (Ser80, Ser81, and Thr84; Figs. 1, 2). Both clusters
are highly conserved (Fig. 2E), indicating that the phosphoryla-
tion of these residues may play critical roles. In agreement, the
Table 3. Crystallographic statistics for synaptotagmin-1 with bound SV2A peptide
phosphorylated at Thr84
Structure/PDB code SYT1–SV2A peptide/4v11
Data collection
Space group P 1 21 1
Wavelength (Å) 1.54178
Unit-cell parameters
a, b, c (Å) 46.05, 41.43, 48.01
,, (°) 90.00, 96.59, 90.00
Resolution range (Å)a 31.28–1.95 (2.02–1.95)
n reflections 25874 (2156)
Unique reflections 13172 (1209)








Wilson B (Å2) 10.0
Overall average B (Å2) 11.0
n protein residues (atoms) 160 (1286)
n ligands (atoms) 3 Ca 2, 1 glycerol (9)






Bond lengths (Å) 0.007
Bond angles (Å) 1.004


















, where Ihkl,i is the intensity of the ithmeasurement of reflection hkl and Ihkl









obs , where F
obs is the observed structure factor, and F calc is the calculated structure
factor.
dRfree is the same as Rwork except calculated with a subset, 5%, of data that are excluded from the refinement
calculations. The PDB accession code is 4V11.
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key residue Thr84 is conserved in both SV2B and SV2C, as is
Ser81. Because phosphorylation of substrates by CK1 kinases is
facilitated by an acidic residue or priming phosphorylation at the
3 position (Flotow et al., 1990; Meggio et al., 1991), phosphor-
ylation of Ser81 primes for phosphorylation of Thr84. Consistent
with this, mutation of Ser80 and Ser81 prevented phosphoryla-
tion of Thr84 in SV2A overexpressed in HEK293 cells (Table 2).
When we crystallized the C2B domain of synaptotagmin-1 with
the Cluster-2 Ser80, Ser81, and Thr84 triply phosphorylated pep-
tide, we observed no electron density for the phosphorylated
Ser80 and Ser81, indicating that these residues may not be inter-
acting specifically with the C2B domain. Consistent with this, the
triply phosphorylated peptide did not interact with the
synaptotagmin-1C2Bdomainwith higher affinity than the singly
Thr84 phosphorylated peptide (Fig. 4). Therefore, it is likely that
the principal role of Ser80 and Ser81 is to prime Thr84 for phos-
phorylation by CK1 family kinase(s) rather than to mediate in-
teraction with synaptotagmin-1.
Which CK1 family member(s) phosphorylate SV2A at
Cluster-1 and Cluster-2 sites in vivo? To address this question,
systematic analysis of SV2A phosphorylation in CK1 isoform
knockdown or knock-out systemsmay be required. This analysis
may be complicated by the redundancy ofmultiple CK1 isoforms
phosphorylating SV2A, as suggested by our in vitro experimenta-
tion (Fig. 1). None of the widely used pan CK1 inhibitors de-
scribed to date (D4476, CKI-7, and IC261) are sufficiently potent
(in vitro IC50 values1M), or selective (see http://www.kinase-
screen.mrc.ac.uk/kinase-inhibitors), to be used to determine
which CK1 isoforms regulate SV2A phosphorylation in vivo. Al-
though certain CK1 family kinases tested, such as TTBK1,
TTBK2[1–316], and CK1, phosphorylated SV2A more effi-
ciently in vitro than other familymembers (CK11 and CK1), it
is not possible to rule out that this was a result of the recombinant
kinases possessing low intrinsic activity because of their expres-
sion in E. coli and/or lack of factors required to promote phos-
phorylation of SV2A by CK1 kinase(s). The finding that
phosphorylation of Ser80 and Ser81 promotes phosphorylation
of Thr84 in vivo (Tables 1, 2) is consistent with CK1 family ki-
nase(s) known to require a 3/4 phosphorylation priming
mechanism.
Figure 5. Crystal structure of Thr84 phosphorylated Cluster-2 peptide bound to synaptotagmin-1 C2B domain. A, A ribbon diagram of the synaptotagmin-1 C2B domain (residues
270 – 422) bound to a peptide encompassing the Cluster-2 region of SV2A (residues 81–90) that is phosphorylated at Thr84 (PDB entry 4v11). The synaptotagmin-1 C2B domain is shown
with strands colored in cyan, helices in magenta, and loops in gray. The backbone of the SV2A peptide, binding at the polybasic region, is colored in yellow. The side chains of residues
of the polybasic region interacting with the SV2A peptide are shown as stick models. The two Ca 2 ions, binding between loops 1 and 3, are shown as green spheres. B, Electrostatic
surface representation of synaptotagmin-1 with the bound SV2A peptide. The negatively charged phosphate group of the SV2A peptide is binding to the positively charged surface area
at the polybasic region of synaptotagmin-1. Negative charge (acidic) is shown in red and positive charge (basic) in blue. The electrostatic map is contoured from 5 to 5 kTe. C,
Stereo-image and close-up analysis of the pocket on the C2B domain that interacts with Thr84 phosphorylated residue. The three highly conserved surface-exposed Lys residues on
synaptotagmin-1 (Lys314, Lys326, and Lys328) interact with Thr84 of SV2A, and distances between the-amino groups of the lysine residues and the phosphate group of phosphorylated
Thr84 are shown in angstroms. These Lys residues are distributed on anti-parallel sheets 3 and 4, and their side chains form a specific binding pocket that precisely accommodates the
phosphorylated Thr84 residue. The 2mFo-dFc map, before manual building of the peptide model and refinement, is shown as gray mesh and was contoured at 1	within 2 Å of the SV2A
peptide. D, Fluorescence polarization analysis of WT and indicated Lys substitution mutants (K314A, K326A, K328A, and K326A/K328A) of synaptotagmin-1 C2B domain and peptide
encompassing Cluster-2 region of SV2A (residues 76 –90), which was either phosphorylated at Thr84 or unphosphorylated as a negative control. Data points and error bars represent
mean SD (n 3), and similar results were obtained in at least two separate experiments for all data shown in this figure.
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Mapping of the synaptotagmin-1–SV2A
interaction site
The N terminus of SV2A interacts with
synaptotagmin-1 (Schivell et al., 1996,
2005), and this interaction is enhanced by
CK1 phosphorylation in vitro (Pyle et al.,
2000). Our data establish that CK1 phos-
phorylation of Thr84 promotes the inter-
action of SV2A with the C2B domain of
synaptotagmin-1 (Fig. 4). Crystallo-
graphic analysis reveals that the phos-
phorylated Thr84 residue interacts with a
specific pocket on the surface of the
synaptotagmin-1 C2B domain (Fig. 5).
This lies within the “polybasic region”
(Fernandez et al., 2001). This pocket is
formed from three surface-exposed Lys
residues (Lys314, Lys326, and Lys328)
that make hydrogen bonds with the phos-
phate moiety of the phosphorylated
Thr84 residue (Fig. 5). These Lys residues
are conserved in all species of synap-
totagmin-1 we have analyzed and in 13 of
the 17 synaptotagmin isoforms present in
humans, suggesting that these will all pos-
sess the ability to interact with CK1-
phosphorylated SV2 isoforms. The Lys
residues equivalent to Lys326 and Lys328
are absent in the C2A domain of
synaptotagmin-1, likely accounting for its
failure to bind the Cluster-2 Thr84 phos-
phorylated peptide.
The regions surrounding the phos-
phorylated Thr84 binding pocket on the
synaptotagmin-1 C2B domain bind to
other components, including phosphoi-
nositides (Schiavo et al., 1996), adaptor
protein 2 (AP-2; Zhang et al., 1994), cal-
cium channels (Leveque et al., 1992),
other synaptotagmins (Chapman et al.,
1996), and target-soluble N-ethylmaleimide-
sensitive factor attachment protein receptor (t-SNARE) dimers
(Bhalla et al., 2006). NMR analysis (Joung et al., 2012) revealed
that inositol hexaphosphate IP6 binds to a pocket that lies adja-
cent to that for the phosphorylated Thr84 binding pocket. The
phosphate groups on IP6 form key interactions with Lys328,
Thr330, and Lys332 residues in human synaptotagmin-1. Inspec-
tion of the structure of the C2B domain does not rule out the
possibility that the C2B domain could bind simultaneously to the
phosphorylated Cluster-2 SV2A peptide and IP6/phosphoinosi-
tide, with Lys328 functioning as a pivotal residue capable of inter-
acting with both phosphorylated Thr84 and an inositol
phosphate group. Phosphoinositide binding has been proposed
to control the interaction of the C2B domain with the t-SNARE
dimer (Rickman et al., 2004). Thus, Lys328 may act as a molecu-
lar switch, binding either phosphorylated SV2A for its retrieval or
IP6 for t-SNARE-specific interactions. Other studies have sug-
gested that the Lys327 and Lys328 residues (corresponding residues
inhumanSYT1) controlC2Bdimerizationandregulate interactions
with both AP-2 and voltage-gated calcium channels (Chapman et
al., 1998; Grass et al., 2004). Therefore, more work is required to
study the interplay between the interactionof synaptotagmin-1with
CK1-phosphorylated SV2A and other binding components.
Phosphorylation of SV2A controls synaptotagmin-1 retrieval
during SV endocytosis
We found that removal of the phosphorylation-dependent SV2A
interaction by either mutagenesis of the C2B domain, shRNA
knockdown of SV2A, ormutagenesis of T84 on SV2A all result in
increased retrieval kinetics of Syt1–pHluorin. This was surpris-
ing, because disruption of endocytic sorting mechanisms by ei-
ther knockdown of adaptor protein complexes or monomeric
adaptors (Kim and Ryan, 2009; Willox and Royle, 2012; Konon-
enko et al., 2014) ormutagenesis of key endocytosismotifs (Vogl-
maier et al., 2006; Yao et al., 2010; Koo et al., 2011; Foss et al.,
2013) usually result in retarded SV cargo retrieval. This accelera-
tion was not attributable to defective retention of Syt1–pHluorin
in nerve terminals, because retrieval kinetics were identical when
axonal regions were analyzed. Interestingly, accelerated Syt1–
pHluorin retrieval was also observed in neurons derived from
stonin 2 knock-out mice (Kononenko et al., 2013). Stonin 2 is a
synaptotagmin-specific adaptor molecule, and knock-out neu-
rons displayed both accumulation of Syt1–pHluorin at the
plasma membrane and enhanced SV endocytosis kinetics. We
also observed increased plasma membrane accumulation of
Syt1–pHluorin on perturbation of SV2A interactions, but we see
Figure 6. Inhibition of SV2A binding accelerates Syt1–pHluorin retrieval during SV endocytosis.A, Hippocampal neuronswere
transfected with either WT or phospho-null (P-null) SV2A–pHluorin. Grayscale images show that SV2A–pHluorin was correctly
targeted to nerve terminals. Scale bar, 1m. B, Neurons transfected with either WT (blue) or P-null (red) SV2A–pHluorin were
stimulated with a train of 300 action potentials (10 Hz). Graph displays the meanF/F0 time course for SV2A–pHluorin SEM
normalized to the peak of stimulation (n 5 WT, n 4 P-null). C, Neurons were transfected with either WT or K326/328A
Syt1–pHluorin. Grayscale images show that Syt1–pHluorin was correctly targeted to nerve terminals. Scale bar, 1m. Surface
expression of either Syt1WT–pHluorin or Syt1[K326/328A]–pHluorin displayed as a percentage of total pHluorin SEM (**p
0.004).D, Neurons transfectedwith eitherWT (blue) or K326/328A (red) Syt1–pHluorinwere stimulatedwith a train of 300 action
potentials (10 Hz). Graph displays the meanF/F0 time course for Syt1–pHluorin SEM normalized to the peak of stimulation
(significantly different between time points 128–140 s; p 0.05; n 8 for both WT and K326/328A). In both B and D, the bar
indicates period of stimulation.
2504 • J. Neurosci., February 11, 2015 • 35(6):2492–2507 Zhang et al. • SV2A Phosphorylation Controls Synaptotagmin Traffic
no effect on global SV endocytosis. The most likely explanation
for these results is that Syt1–pHluorin is being retrieved by a
parallel endocytic mode with faster retrieval kinetics than classi-
cal clathrin-mediated endocytosis. It is possible that accumula-
tion of Syt1–pHluorin at the plasmamembrane may even trigger
this mode. Thus, although there is an underlying defect in
Syt1–pHluorin retrieval via clathrin-mediated endocytosis (re-
flected in increased surface accumulation in
resting neurons), the retrieval of Syt1–pHluo-
rinnewlydepositedon thecell surfacebyneu-
ronal activity could be mediated by an
alternate endocytosismode.
SV2A is a phospho-dependent
synaptotagmin-1 chaperone
We propose that SV2A could act as a
phospho-dependent chaperone for the ef-
ficient post-exocytic trafficking of synapto-
tagmin-1, in addition to AP-2 and stonin
2. The requirement for a classical adaptor
protein complex, a monomeric adaptor
protein, and SV chaperone has close
parallels with recent investigations of the
retrieval mechanism of the essential vesi-
cle v-SNARE synaptobrevin II. Synapto-
brevin II has no canonical motif for AP-2
binding, so the monomeric adaptor
AP180 clusters this SV cargo by simulta-
neously binding to AP-2 and the SNARE
motif of synaptobrevin II (Koo et al.,
2011). However, the SV protein synapto-
physin is also essential for efficient synap-
tobrevin II retrieval (Gordon et al., 2011;
Gordon andCousin, 2013). Thus, interac-
tions between SV cargo at the nerve termi-
nal plasma membrane may serve to aid
cargo clustering, present cargo in the cor-
rect conformation for adaptor proteins,
or restrict entry into ectopic “dead-end”
complexes (Gordon and Cousin, 2014). A
recent quantitative study demonstrated a
similar copy number for both SV2A and
synaptotagmin-1 on the SV (Wilhelm et
al., 2014), supporting a potential chaper-
one role for SV2A.
HowmightSV2Acontrol synaptotagmin-
1 retrieval in concert with other clathrin
adaptor molecules? Stonin 2 primarily in-
teracts with the C2A domain (Jung et al.,
2007), meaning that both SV2A and
stonin 2 could interact simultaneously
with synaptotagmin-1 via differentC2do-
mains. In addition, both stonin 2 and
SV2A interact with AP-2 via canonical in-
ternalization motifs (Diril et al., 2006;
Yao et al., 2010). Thus, after SV fusion,
synaptotagmin-1 will be sequestered by
both stonin 2 and SV2A for clustering
with AP-2. In agreement, SV2A binding
increases the AP-2 affinity for the
synaptotagmin-1 C2B domain (Haucke
and De Camilli, 1999; Haucke et al.,
2000). Because the SV2A–synapto-
tagmin-1 interaction is phosphorylation dependent, this model
predicts that SV2A is only phosphorylated after exocytosis is
complete, allowing synaptotagmin-1 on the SV to participate in
evoked neurotransmitter release. This suggests that the phos-
phorylation state of presynaptic chaperones may be a regulatory
mechanism that contributes to the efficiency of SV cargo re-
trieval. Therefore, it will be of great future interest to determine
Figure 7. P-null SV2A does not rescue Syt1–pHluorin retrieval after shRNA knockdown. A, Images of cultures transfected with
shRNA–Syt1–pHluorin vectors that are either empty or contain oligonucleotides against SV2A (shRNA1). Grayscale panels high-
light transfected neurons (GFP), whereas false color panels display endogenous SV2A revealed by immunofluorescence staining.
Arrowshighlightnerve terminals. Scalebar, 1m.B, Neurons transfectedwithWTSyt1–pHluorin andeither empty (blue) or SV2A
shRNA (shRNA1, red)were stimulatedwith a train of 300 action potentials (10 Hz). Graph displays themeanF/F0 time course for
Syt1–pHluorin SEM normalized to the peak of stimulation (significantly different between time points 96–140 s; p 0.05;
n 7 empty, n 5 shRNA1). C, Neurons transfected with a pSUPER vector expressing both Syt1–pHluorin and shRNA1 were
coexpressed with either mCer empty vector (mCer), WT mCer–SV2A, or T84A mCer–SV2A. Neurons were stimulated as in B, and
the graph displays the meanF/F0 time course for Syt1–pHluorin SEM normalized to the peak of stimulation (mCer and WT
traces significantly different between 60 and 200 s; p 0.05, T84A andWT traces significantly different from68–200 s; p 0.05;
n 5mCer, n 6WT, n 7 T84A).D, Surface expression of Syt1WT–pHluorin in neurons expressing a combination of empty or
shRNA1pSUPERvector andmCer,WT, or T84AmCer–SV2Adisplayedas apercentageof total pHluorin SEM(*p0.05, ***p
0.001 to empty/mCer; ###p 0.001 to shRNA1/mCer; p 0.05 to shRNA1/WT; n 7 for all except n 5 for shRNA1/T84A).
E, Neurons transfected with WT synaptophysin–pHluorin (Syp–pHluorin) and either empty (blue) or SV2A shRNA (shRNA1, red)
were stimulated as in B. Graph displays the meanF/F0 time course for Syp–pHluorin SEM normalized to the peak of stimu-
lation (n 9 empty, n 6 shRNA1, p 0.05). In B, C, and E, the bar indicates the period of stimulation.
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where (on SVs and/or plasma membrane) and when (before,
during, or after action potential stimulation) SV2A is phosphor-
ylated by a CK1 family kinase.
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